

INTERNATIONAL
TRADE CENTER
HOUSTON, TEXAS

國際貿易中心

INTERNATIONAL
TRADE CENTER

WERE BUILD BRIDGES TO
INTERNATIONAL
BUSINESS

國際化商貿 從這裡出發

INTERNATIONAL TRADE CENTER-HOUSTON

Southern News Group
Corporate Office-Houston, Texas USA

11110 Bellaire Blvd., Suite 200, Houston, Texas 77072
Tel: (832) 448-0190 Fax: (281) 498-2728

全美最大華裔獨立多媒體集團·報業·電視·黃頁·移動傳媒
The Largest Asian Independent Multi-Media Group in USA Newspaper·Television·Yellowpages·Design

美南
日報

分類廣告 C1
SOUTHERN NEWS GROUP
美南新聞報業電視傳媒集團總社

YELLOW
SHEET

美南新聞日報(總社)·華府新聞日報·達拉斯日報

E-Newspaper: www.scdaily.com

Tel: 281-498-4310 Fax: 832-399-1355 E-mail: cla@scdaily.com

wechat: AD7133021553

4月11日 星期一

PRSR: STD US POSTAGE PAID ALIFE, TX PERMIT #16
美國政府指定刊登法律條文廣告有效刊例

分類廣告價目表 CLASSIFIED AD. RATE				
週數 Week	一週	二週	三週	一月
格數 Size	1 wk	2 wks	3 wks	1 mon
1 格 (1unit)	\$45	\$80	\$105	\$125
2 格 (2units)	\$90	\$160	\$210	\$250
3 格 (3units)	\$135	\$240	\$315	\$375
4 格 (4units)	\$180	\$320	\$420	\$500
EFFECTIVE: 從2009年11月1日起實施				

Place Your AD

一通電話, 萬事OK

By phone, Fax, Email or in person:

電話·傳真·電郵·上網或登門刊登

Call(電話服務專線): 281-498-4310

Fax (傳真): 832-399-1355

Email(電郵): cla@scdaily.com

Wechat(微信): AD7133021553

Click(上網): www.scdaily.com

Stop by(登門): 11122 Bellaire Blvd
Houston TX 77072

Business Hours:

Monday-Friday:

8:00am-4:00pm

上班時間:

週一至週五:

上午八時至下午四時

分類廣告 公告欄 (訂稿規則)

●分類廣告請預付廣告費,如中途停刊者,恕不退還費用。

●刊登一個月以下者,廣告均不得改稿,若需改稿每次酌收費用5元

●本報接受 VISA 及 MASTER 信用卡付費,如電話(Tel)/ 微信 Wechat / 傳真(Fax), 訂稿委刊-請告知信用卡號碼/姓名/有效期限/CVV 號/郵編/地址號。其訂稿如有錯誤由客戶自行負責,恕不補登。

●截稿時間: 星期一至五 2:30pm, 平時/周六日請微信: AD7133021553

截稿或之前訂稿,立即上網,其稿將在第二天登報。

100

Restaurant
Hiring

餐館服務

珍寶海鮮城 誠聘
點心師傅、點心熟籠、點心幫手
推車、傳餐、帶位。
需少許英文,全工或半工均可
請電: 281-988-8898 或親臨面談
11215 Bellaire Blvd, Houston, TX 77072

100

Restaurant
Hiring

餐館服務

新皇宮點心海鮮酒樓 (ChinaBear)
『高薪』誠聘:經理,企枱,收銀,帶位
廚房:煎炸,蒸籠,腸粉,炒鍋,抓碼,油爐
意者請電 New Palace 或親臨面談:
281-240-8383 713-303-8998
12755 Southwest Fwy, Stafford TX 77477

堂吃外賣店
誠聘
有經驗炒鍋師傅一名
可報稅。位 KATY。
意者請電
832-282-3492
另外餐館低價出售,
客源穩。

餐館招聘炒鍋
距離休斯頓2小時
車程,包吃包住,
有意者請致電:
210-380-2645

中餐館誠聘
●半工外送員
●半工收銀接電話打包
●全工炒鍋
有經驗,要報稅
離中國城15分鐘
4670 Beechnut
713-307-2882

Mamak 糖城店
Malaysian Restaurant
誠聘企枱,環境好,
小費高,新手可培訓。
有意者請電:
346-874-7913
每周二公休

中國城中餐館
『高薪』
聘請廣東炒鍋,
每周工作50個小時,
每周休息2天
意者請電:黃師傅
281-210-8392

糖城翠苑中餐館
誠請 點心助理。
全職/兼職
有意者請電:
832-606-3731

餐館請人
靠近 249
『高薪』誠聘
炒鍋,打雜,外送員
企枱,聽接電話。
意者請電聯:
281-966-5342

黃金水餃請人
中國城黃金廣場內
新優誠請廚房員工
全工。需有身份
請 11am-9pm 來電:
713-270-9996
281-881-9885

壽司餐館請人

Restaurant Hiring

*超市內壽司吧
急徵工作人員一名
男女/年齡不拘
需有些經驗
待遇 \$\$ 優優優 \$\$
請 5 點後電或簡訊
832-660-2521

壽司鐵板店招工
位 Downtown
誠招
收銀及廚房幫工
周一到周五
電話詳談:
832-520-6015

HEB 超市內壽司吧請人
HEB, Kroger Sushi Roll Available People Priority
(Training Available) 10 mins from Pearland
Medical Center/ Hwy-288 / Rice University
Address: 6055 South Freeway, Houston, TX
Please call: 832-808-0206
誠請全工/半工壽司師傅及廚房幫手,
懂少許英文即可,近醫學中心及 Rice 大學

日本餐館誠聘
全職壽司及鐵板師傅
位 Missouri City 近糖
城,需有經驗,做事認真
負責能報稅,薪資面議
有意向請聯系
912-381-5292
346-303-3218

中日式餐館誠聘
●炒鍋師傅
●油爐師傅
意者請電:
832-766-1986

日本餐館誠請
壽司師傅或學徒
企枱及帶位
全工/半工均可
需工卡,請親臨或電:
713-781-6300
6345 Westheimer

糖城中餐館
誠請前台和外送員,
全工或半工均可,
需英文流利,可報稅。
有意者請電
832-866-2625

Japanese Rest
is hiring ● Servers
(Waiter/Waitress)
● Sushi Help
Please call:
832-693-6534
8236 Kirby Dr. #200
Houston, TX 77054

西南區日餐
鐵板店『高薪』招聘
● Hibachi 鐵板師傅
● 日餐廚房師傅
● 企枱(Water/Waitress)
全職/半職均可
提供住宿,意者請電:
832-289-1003

日本餐館請經理
位 Missouri City 近
Sugar Land, 誠請
full time/part time 經理
需有經驗,說英語,
做事認真負責能報稅,
工資\$200/天,請聯系:
912-381-5292
346-303-3218

中日式餐館誠聘
1960/249, 聘:油鍋,炒鍋
Sushi 師傅, Sushi 學徒,
工資面議,聘男女企枱:
人事簡單,有午休,有經
驗優先,無經驗可培訓,
也歡迎在讀學生。電話:
346-404-7082
電話不接可短信

200
餐館租售
Restaurant
for sale

中餐外賣店售
Spring 區, 1700 呎
房租 \$4570。
有送餐,生意 \$75,000
合同剩 7 年半,
開店 12 年,價格面議
832-748-1728
聯系人:阿輝

中餐堂吃外賣店
出售
離中國城 20 分鐘,
設備齊全,客源穩定,
接手即賺錢。
發展空間大,
歡迎看店,聯系電話:
917-775-2976

*外賣店出售
近中國城,交通方便
墨西哥旺區
1600 呎,設備齊全,
租金低(包水)
目前無營業,
請電:非誠勿擾
832-661-8881

28 年老店轉讓
近 Memorial 公園
610 / I-10
美式中餐堂吃外賣店
誠意轉讓,生意穩定
電話:非誠勿擾
713-880-1690

*賺錢餐館轉讓
位 Galleria 區
1000 呎賺錢外賣店
房租 2500, 生意 5 萬
有意者請電:
832-661-5840

創業良機
在高銷售額的超市內
Sushi Bar 出售
13 年老店,東主退休
~月銷 3 萬以上~
有意者請電或簡訊:
832-858-3378

堂吃外賣店
出售
生意好,地點佳。
意者請電:
713-307-2540

美式中餐館轉讓
近 Katy 6 號公路
美式中餐堂吃外賣店
誠意轉讓,裝修新穎店
面積約 1750 呎
生意穩定有上升空間
電話:非誠勿擾
346-235-6769

*餐館轉讓
位 FountainView Dr
450 呎,租金 \$1000
適合家庭經營
設備齊全,業主退休
意者請來電:
408-601-9239
346-319-4769

轉讓賺錢堂吃
兼外賣店
離中國城 15 分鐘車程
長年經營生意穩定。
意者請聯系:
713-373-2947
非誠勿擾!

穩賺中餐館出售
德廉又有好口碑中餐館
位德州南部,近邊界約
4000 呎,因老闆退休,月
生意 7 萬以上,半價出售,
隨時歡迎看店。電:蘇
956-792-4730
956-778-2176

生意好,辦公樓內快餐熟食店售
絕佳機會!! 售價 \$49,000
位於 59 公路及 610 西交界
Office Deli for Sale (Great Opportunity)
Currently in Business Asking Price \$49,000
SW Freeway and 610W.
(English Speaking Only)
請英文電: 713-985-9829

*糖城餐館出售
地點極佳,營業 6 天
面積 1600 呎,適合家庭生意,
易管理,因人手不足轉讓。
有意者請電:
832-788-6688

*亞洲餐館(中越韓式)出售
將最好的中國/亞洲美食集中在一起,供饕餮家
品嘗。能源走廊休斯頓地區。1800 平方英尺。
售價僅為 \$85,000 美元。餐廳按原樣出售。
The best of a Chinese / Asian Cuisine
Energy Corridor Houston area.
1800 sqft. Selling price \$85000 only .
Landlord give back \$20,000 for remodel restaurant.
Please call : 281-725-4664

餐館轉讓
休斯頓 610 Loop 裡面中餐館轉讓,地理
位置絕佳,周圍環繞辦公室及富人住宅區。
面積 2200SF,大小適中,適合各類餐廳,
生意 8 萬+。廚房設備齊全,
有 walk in cooler 和 walk in freezer。
因為忙接不到電話,意者請發短信:
713-898-4332 (非誠勿擾)

***10年正規床腳店,薪優急聘**
位 10號 99大華超市附近
高級床腳店,誠徵**女按摩師**:大費高,
收入穩定,下班早.自駕車,可報稅
意者請電: **713-468-3799**

***誠招女按摩師**
白人區,客人高素質
正規,有執照, 43歲以下。
日入\$200-\$500
意者請電:**832-526-1155**
●另有多家按摩店合作/出售

美南網站



專精各類移民/專精各類福利/老人公寓申請

- 親屬移民,家屬申請,婚姻綠卡等等。
- 低收入福利,紅藍卡申請,白卡申請,糧食券,現金補助,租房補助,家庭能源電器費用補助。
- 可幫健康不佳,行動困難老人申請公寓。

歡迎電話咨詢：713-815-5011 / 281-888-9923

10700 Richmond Ave, ste 241 Houston, TX 77042

DPS 指定王朝駕校路考第三考場
DPS 路試考官, 全權下放至百利駕校教練路考試
 在本校一天可完成筆試,
 取得 permit 後可安排路考, 不用排隊等 30 天
 ● 筆試班: 每星期一至六上課, 務必預約。
 ● 路考班: 務必預約。 考路試, 務必預約。
 ● 安全班: 隨時開課。 開課, 務必預約。
 電話: **832-633-5555** 周師傅
832-983-9509 Tom 發哥



德州帶槍執照
中國城軍火庫
 可在全美38州攜帶
 全課程半天完成\$100
 (外州駕照可申請)
 各式槍枝買賣/交換
9896 Bellaire #G1
 (黃金廣場內)
281-236-4723

Gun License
申請帶槍執照



專收購舊車壞車
 舊、壞車
 動或不動
 一律高價收購
 中英粵越。電話：
713-482-9267

- 分類廣告請預付廣告費，如中途停刊者，恕不退還費用。
- 刊登一個月以下者，廣告均不得改稿，若需改稿每次酌收費用5元
- 本報接受VISA及MASTER信用卡付費，如電話(Tel)或傳真(Fax)訂稿委刊，請告知信用卡號碼/姓名/有效期限/ CVV 號/ ZIP code / Address 號，其訂稿如有錯誤由客戶自行負責，恕不補登。
- 截稿時間：星期一至五 2:30pm，**平時/周六日請微信:AD7133021553**
截稿或之前訂稿，立即上網，其稿將在第二天刊登報紙。

木易裝修
承接房屋大小工程
舊屋翻新,廚房浴室
地板瓷磚,水電木工
涼棚圍欄,高壓清洗
價格公道,免費估價
歡迎來電諮詢:楊
281-755-9988

榮盛裝修
商業住宅,水電木工,
地磚地板,浴室櫥櫃,
內外油漆,大理石安裝
小修小補.
質量第一,誠信價優!
請電: Sam 劉
832-606-7672

吳氏專業裝修
執照# LI 0019006
庭園灑水,庭園設計,籬笆
內外油漆翻新,涼棚涼臺
洗衣機,乾衣機,洗碗機,
水龍頭,地板,地磚,廁浴,
更新,水務維修,電路修換.
832-818-3185 國粵語

宏達建築裝修公司
政府註冊.百萬保險.15年經驗
承接：商業/住宅的
翻新與改造等工程。
誠信為本價格公道，另招裝修師傅
中英 Andy **801-739-5866**
中 蘇師傅 **832-359-2367**

美滿裝修
22年經驗,專精商業住宅
理石廚櫃,地板,磁磚,浴室改建,內外油漆,
門窗,水電,涼棚,圍欄及屋頂翻新.
誠信+優惠+專業 特價 & 保修二年
832-419-5588張 ●另請工人

Mario Chavez 專業油漆
承接 商業/住家. 免費估價 **Free Estimate**
Painting, Re-paint, Pressure Washer, Staining,
Drywalls Sheetrock & Texture, Carpenter,
Siding & Remodeling, Ceramic & Laminate Flooring
油漆, 高壓清洗, 染色, 壁板, 石膏板, 木工, 地板磁磚
Call 英文電: **832-964-3030**
5019 Ridgehaven Dr. Houston, TX 77053



If you would like to share news or information with our readers, please send the unique stories, business

news organization events, and school news to us including your name and phone number in case more information is needed.

For news and information consideration, please send to News@scdaily.com or contact

John Robbins 281-965-6390
Jun Gai 281-498-4310

Publisher: Wea H. Lee
President: Catherine Lee
Editor: John Robbins

Address: 11122 Bellaire Blvd.,
Houston, TX 77072
E-mail: News@scdaily.com



Inside C2

Southern DAILY

Make Today Different

Southern Daily News is published by Southern News Group Daily

Monday, April 11 2022|

Shanghai widens COVID testing as other Chinese cities impose curbs

SHANGHAI, April 8 (Reuters) - Shanghai on Friday announced a record 21,000 new cases and a third consecutive day of COVID testing as a lockdown of its 26 million people showed no sign of easing and other Chinese cities tightened curbs - even in places with no recent infections.

Beijing authorities intervened in Shanghai after its failure to isolate COVID by locking the city down in stages, and insists that the country stick to its zero-tolerance policy to prevent its medical system from breaking down.

Authorities across China, which have mostly managed to keep COVID at bay for the last two years, are stepping up coronavirus control measures, including movement restrictions, mass testing and new quarantine centres.

Cities that sprang into action this week include Zhengzhou, in central Henan province, which on Thursday said it would test all 12.6 million residents after finding a few asymptomatic cases.

Beijing has strengthened regular screening for employees in the city's key sectors, requiring all staff at elderly care agencies, schools and institutions handling imported goods to take tests at least once a week.

In Shizong county in southwest China's Yunnan province, shops were shut, transport suspended and residents barred from leaving their towns or villages.

Nomura this week estimated that 23 Chinese cities have implemented either full or partial lockdowns. The cities collectively are home to an estimated 193 million people and contribute 22% of China's GDP. These include Changchun, a major manufacturing hub that has been locked down for 28 days.

Ernan Cui, an analyst at Gavekal Dragonomics who studied COVID policies announced by China's 100 largest cities, said most were choosing to keep restrictions in place even after case numbers returned to zero.

The curbs "suggest that the economic impact of the various lockdowns will not ease in a matter of days or even weeks", she said in a note.

If Shanghai's lockdown continues throughout April the city will suffer a 6% loss in GDP, amounting to a 2% GDP loss for China as a whole, ING Chief Economist for Greater China Iris Pang said in a note.

White House press secretary Jen Psaki said in a briefing on Friday that the Biden administration was closely monitoring the lockdown in Shanghai, noting that it could cause delays for air cargo. WIN2VE032

'THUNDEROUS' ACTION

Shanghai's outbreak has surpassed 130,000 cases in total, far exceeding the approximately 50,000 symptomatic cases recorded in the original outbreak in the central city of Wuhan, where the virus was first detected in late 2019, although Chinese authorities did not start reporting asymptomatic cases until after Wuhan's peak.

Stories of crowded and unsanitary central quarantine centres and fears of family separation have driven calls for home quarantine in Shanghai.

The Shanghai government has started



allowing some close contacts to isolate at home and on Wednesday eased its policy of separating infected children from their parents.

However, food supply remains a concern with residents, due to a shortage of couriers.

Idemiologist at the China Center for Disease Control and Prevention, said on its Weibo account that action taken in Shanghai had to be "thunderous" to cut off the chain of transmission.

In theory, he said, if multiple rounds of PCR testing were conducted in mega-cities with populations as large as 27 million within 2-3 days, they could reach zero cases "on the community level" within 10 days to two weeks.

Of Shanghai's cases, just one is suffering severe symptoms and is under treatment, a health official said on Friday.



On Friday afternoon results for hashtag "Shanghai buy food" were blocked on the Twitter-like social media site Weibo.

Weibo did not immediately respond to a request for comment.

Shanghai has not indicated when it may lift its lockdown.

Late on Thursday, Wu Zunyou, chief ep-

恆豐銀行

American First National Bank

SecureAlerts

Purchase made?

Money withdrawn?

Check exceeds threshold?

快速 便捷 安全

24 隨時隨地
掌握您的帳戶

Houston Area:

Main Office	Spring Branch	Katy Branch	Harwin Branch	First Colony Branch	Sugar Land Branch
713-596-2888	713-273-1838	281-762-6688	713-273-1888	713-596-2588	281-762-6699

Dallas Area:

Richardson Branch	Harry-Hines Branch	Legacy Branch	Carrollton Branch	Arlington Branch	Garland Branch
972-348-3488	972-348-3433	972-348-3466	972-428-5088	817-261-5585	972-272-3375

Nevada Area:

Las Vegas Branch	Pahrump Branch	Amargosa Branch	Henderson Branch
702-777-9988	775-751-1773	775-372-1100	702-216-5500

California Area:

City of Industry Branch	Alhambra Branch	Arcadia Branch
626-667-3988	626-863-1980	626-321-4455

FDIC LENDER

Volkswagen rejects shareholder push for climate lobbying disclosures

BERLIN, April 9 (Reuters) - Volkswagen (VOWG_p.DE) has rejected a shareholder proposal for it to explain how its lobbying activities align with its climate goals - something two of the carmaker's leading competitors have already promised to do, one of the investors said on Friday.

A filing by a group of seven shareholders said that while Volkswagen does disclose its trade association memberships, it should go further and say whether the associations' aims are compatible with its emissions-cutting targets.

Fellow carmakers Mercedes-Benz (MBGn.DE) and BMW (BMWG.DE) have already committed to doing that.

"The Board is failing to deliver transparent oversight of the company's climate lobbying," said Charlotta Sydstrand, sustainability strategist at Swedish pension scheme AP7, one of the shareholders involved in the proposal.

Her comments were included in a statement issued by the Church of England Pensions group, which also backed the filing.

The statement said Volkswagen had rejected the proposal on the grounds that the issue was deemed to be beyond the competence of the general meeting.

Volkswagen was not immediately available for comment.

Other supporters of the proposal included Britain's biggest listed asset manager Schroders and a range of Swedish pension funds.

Pressure by investors on climate-related issues is growing rapidly.

Last week, 34 investors managing more than \$7 trillion in assets warned 17 of Europe's largest companies, including Volkswagen, they could challenge board directors over their accounting of climate risks. "Investors cannot understand the true value of a company without knowing the embedded climate risks," Natasha Landell-Mills, partner and head of stewardship at investment manager Sarasin & Partners, one of the signatories to the letters, said in an interview.

Others to sign include the fund arm of HSBC (HSBA.L), French public



The logo of German carmaker Volkswagen is seen on a rim cap in a showroom of a Volkswagen car dealer in Brussels, Belgium July 9, 2020. REUTERS/Francois Lenoir/ File Photo

pension scheme ERAFP, and BMO Global Asset Management EMEA, part of U.S. asset manager Columbia Threadneedle.

Investors have tried to press the companies on the issue before. In 2020, through the Institutional Investors Group on Climate Change, they laid out a series of steps boards needed to take to align their accounts with the Paris Agreement on climate, including changing key accounting assumptions.

The investors found that most companies failed

to adequately respond, prompting the latest string of letters warning boards they faced opposition at their upcoming annual general meeting. [read more](#)

"From next voting season you should increasingly expect to see investors vote against Audit Committee directors' reappointment, where high-risk companies fail to meet the expectations," the letters said.

Editor's Choice



A migrant taking part in a caravan heading to the northern border sleeps on the banks of a river, in Santo Domingo Zanatepec, Mexico November 11, 2021. REUTERS/Jacob Garcia



Olena, the mother of Denys Snihur, 25, a border guard-turned-soldier, killed by Russian shelling in the northern town of Ovruch, mourns her son during his funeral at the Lychakiv Cemetery, in Lviv, Ukraine, March 21, 2022. REUTERS/Zohra Bensemra



A girl walks outside a migrant camp near the El Chaparral border crossing in Tijuana, Mexico November 8, 2021. REUTERS/Toya Sarno Jordan



A view of a destroyed Ukrainian government administration building following shelling in Mykolaiv, Ukraine, April 8, 2022. REUTERS/Ueslei Marcelino



Locals sit in front of their house in the village of Andriivka, in the Kyiv region, Ukraine, April 7, 2022. REUTERS/Marko Djurica



Mariya, 77, whose daughter and son-in-law died under the rubble of a building destroyed by Russian shelling, cries, amid Russia's invasion of Ukraine in Borodyanka, in Kyiv region, Ukraine April 8, 2022. REUTERS/Gleb Garanich

Promising COVID Research Developments

Two More Life-Saving COVID-19 Drugs Discovered



Two more life-saving drugs have been found that can cut deaths by a quarter in patients who are sickest with Covid.

By Guest Writer Michelle Roberts Health editor, BBC News online

Compiled And Edited By John T. Robbins, Southern Daily Editor

The anti-inflammatory medications, given via a drip, save an extra life for every 12 treated, say researchers who have carried out a trial in NHS intensive care units. Supplies are already available across the UK so they can be used immediately to save hundreds of lives, say experts.

There are over 30,000 Covid patients in UK hospitals - 39% more than in April.

The UK government is working closely with the manufacturer, to ensure the drugs - tocilizumab and sarilumab - continue to be available to UK patients.

As well as saving more lives, the treatments speed up patients' recovery and reduce the length of time that critically-ill patients need to spend in intensive care by about a week.

Both appear to work equally well and add to the benefit already found with a cheap steroid drug called dexamethasone.


Life-saving coronavirus drug 'major breakthrough'

Although the drugs are not cheap, costing around £750 to £1,000 per patient, on top of the £5 course of dexamethasone, the advan-

tage of using them is clear - and less than the cost per day of an intensive care bed of around £2,000, say experts.

Lead researcher Prof Anthony Gordon, from Imperial College London, said: "For every 12 patients you treat with these drugs you would expect to save a life. It's a big effect."

In the **REMAP-CAP trial** carried out in six different countries, including the UK, with around 800 intensive care patients: Nearly 36% of intensive care COVID patients receiving standard care died. The new drugs reduced that by a quarter, to 27%, when given to patients within 24 of them entering intensive care.



Prof Stephen Powis, NHS national medi-

cal director, said: "The fact there is now another drug that can help to reduce mortality for patients with Covid-19 is hugely welcome news and another positive development in the continued fight against the virus."

Health and Social Care Secretary Matt Hancock said: "The UK has proven time and time again it is at the very forefront of identifying and providing the most promising, innovative treatments for its patients.

"Today's results are yet another landmark development in finding a way out of this pandemic and, when added to the armoury of vaccines and treatments already being rolled out, will play a significant role in defeating this virus."

The drugs dampen down inflammation, which can go into overdrive in Covid patients and cause damage to the lungs and other organs. Doctors are being advised to give them to any Covid patient who, despite receiving dexamethasone, is deteriorating and needs intensive care.

Tocilizumab and sarilumab have already been added to the government's export restriction list, which bans companies from buying medicines meant for UK patients and selling them on for a higher price in another country. The research findings have not yet been peer reviewed or published in a medical journal (Courtesy <https://www.bbc.com/>)

Related

Early Plasma Trial Promising In Adults 65+ With Milder COVID-19

— NNT* of 7 to prevent one case of severe illness in Argentine trial

(NNT is a simple statistical concept called the "Number-Needed-to-Treat", or for short the 'NNT'. The NNT offers a measurement of the impact of a medicine or therapy by estimating the number of patients that need to be treated in order to have an impact on one person. The concept is statistical, but intuitive, for we know that not everyone is helped by a medicine or intervention — some benefit, some are harmed, and some are unaffected. The NNT tells us how many of each.)



Older adults hospitalized with milder COVID-19 who received convalescent plasma showed lower risk of developing severe respiratory disease versus patients who received placebo, a randomized trial found. In an intention-to-treat analysis, severe respiratory disease occurred in 16% of COVID-19 patients ages 65 and older receiving convalescent plasma within 72 hours after symptom onset versus 31% of patients receiving placebo (relative risk 0.52, 95% CI 0.29-0.94, P=0.03), reported Fernando Polack, MD, of Fundación INFANT-COVID-19 Group in Buenos Aires, Argentina, and colleagues, in the New England Journal of Medicine.

However, the trial was stopped early at about three-quarters of its projected sample size due to a decline in COVID-19 cases in the region, the authors noted. Evidence for convalescent plasma in COVID-19 has been conflicting from the beginning. Some observational studies showed promise, while more recent research found no benefit among patients with severe COVID-19. But previous studies may have administered them too late, as authors noted antibodies in plasma "must be administered soon after infection in order to be effective." The FDA authorized its use in hospitalized COVID-19 patients in August.

Polack and colleagues pointed up how their trial differed from others: it focused on older adults, who are most affected by the pandemic, and convalescent plasma was given "in a mild stage" with the aim of preventing progression.

"Our primary endpoint" -- severe respiratory illness -- "was an enrollment criterion in previous studies," the group noted.

Patients were enrolled in Argentina from June 4 to Oct. 25. They included patients ages 65-74 with at least one comorbidity, and patients ages 75 and older irrespective of pre-existing conditions. They had tested positive for SARS-CoV-2 and had symp-

toms including fever, unexplained sweating or chills and dry cough for less than 48 hours. Severe respiratory disease was defined as respiration at 30 breaths per minute or more or oxygen saturation of less than 93% on ambient air. They were assessed from 12 hours after infusion to day 15 of trial participation.



Overall, 160 patients underwent randomization. Mean age was 77, and 62% were women. A little more than half were 75 or older. Most patients had pre-existing conditions, with over two-thirds of both groups being treated for hypertension. An intention-to-treat analysis found severe respiratory disease developed in 13 of 80 patients in the intervention group and 25 of 80 in the placebo group, for a relative risk reduction of 48% and a number needed to treat of 7 to avert one episode of severe respiratory disease.

There were no solicited adverse events observed. Four convalescent plasma recipients had life-threatening respiratory disease. Two patients in the intervention group and four patients in the placebo group died.

Polack's group noted that while the trial "lacked the statistical power to discern long-term outcomes," their findings underscored "the need to return to the classic approach of treating viral infections early."

An exploratory finding of the trial was a dose-dependent IgG effect, where donated plasma with IgG titers of 1:3,200 or higher reduced severe respiratory disease by 73% and a number needed to treat of 4. Among the plasma donors in the trial, 71% with titers of 1:3,200 or higher were previously hospitalized.

"Super donors" with IgG titers of 1:12,800 or higher and perhaps immunized persons in the future could contribute to build a therapeutic arsenal," Polack and colleagues wrote. (Courtesy [medpagetoday.com](https://www.medpagetoday.com))

Moderna Vaccine May Work For 'A Couple Of Years'



Compiled And Edited By John T. Robbins, Southern Daily Editor

Jan. 8, 2021 -- The Moderna vaccine -- one of two vaccines now being distributed in the United States -- will "potentially" provide protection against COVID-19 for several years, the biotech company's CEO said, according to Reuters.

But Stephane Bancel said the Massachusetts-based Moderna will have to conduct more research to be definitive about how long the vaccine will work. Because coronavirus vaccines are new, health experts aren't sure how long they'll be effective.

"The nightmare scenario that was described in the media in the spring with a vaccine only working a month or two is, I think, out of the window," Bancel said at an event organized by the Franco-German financial services group Oddo BHF.

"The antibody decay generated by the vaccine in humans goes down very slowly (...) We believe there will be protection potentially for a couple of years."

Bancel went on to predict Moderna would soon prove its vaccine would work against coronavirus variants found in the United Kingdom and other nations, Reuters said.

The U.S. government approved the Moderna vaccine for distribution in the United States on Dec. 17, one week after approving the Pfizer/BioNTech vaccine. Both are now being administered in the United States and the Moderna vaccine was recently approved by the European Com-

mission.

Moderna and Pfizer both use two shots of messenger RNA to create an immune response against the coronavirus. The shots are given about two weeks apart.



Moderna said its vaccine had proven to be 94.1% effective, and 100% effective in severe cases of COVID-19. Pfizer says its vaccine has a similar efficacy, 95%.


The U.S. Department of Health and Human Services has agreed to purchase 200 million doses of Moderna's vaccine and could purchase more.

Despite increasing coronavirus case counts and deaths, distribution of the coronavirus vaccine has lagged in the United States. The CDC says 17.2 million doses have been distributed to the states as of Dec. 6, but only 5.3 million doses have been administered.

Vaccines being produced by AstraZeneca and Johnson & Johnson are still in

COMMUNITY

Why Vaccines Are Critical To Keeping Diseases At Bay



Scientists around the world are racing to develop a vaccine for the novel coronavirus that has killed tens of thousands of people since late December. Dozens of companies and institutions are leading the charge at a record pace, and some already have begun the first phase of clinical trials. Yet researchers continue to warn that it could take at least a year to 18 months before a vaccine is ready for public use—a long time to wait for what many see as the best hope to stem the spread of the SARS-CoV-2 virus, which causes COVID-19.

Most vaccines don't cure diseases; they prevent you from getting infected in the first place. Vaccines contain the same germ (or part of a germ) that causes a disease, but in a killed or weakened state so that it doesn't actually make you sick. The immune system learns about the pathogen, stores information about it, and produces antibodies against it so that the next time it appears, the body can fight it off.

Vaccines have been around only for a couple hundred years, but the concept of inoculating ourselves against diseases has a long history.

The invention of vaccines

Smallpox was one of the early scourges of humankind—and the first and only one to be eradicated with the use of a vaccine. By 430 B.C., humans had figured out that people who survived smallpox developed an immunity to it. Sometime over the next 2,000 years—some say as early as 200 B.C.—people learned how to inoculate themselves against it. Early accounts from China and India in-

dicating that people fought the deadly disease using a technique called variolation, which involved grinding up smallpox scabs and deliberately infecting someone with it by blowing it up a nostril or scratching it into their skin. Variolation caused a milder form of the disease and was far from perfect: Not only was there still a 2 to 3 percent fatality rate, but the infected could pass on smallpox. Still, by the early 18th century, the technique had become popular in Europe and the Americas.



In 1796, an English doctor named Edward Jenner revolutionized the way we approach diseases like smallpox. He showed that inoculation using a weakened strain of cowpox—a mild zoonotic disease that at the time typically transferred from cattle to humans—could also protect against smallpox. During the next several decades, Jenner's vaccination method gradually replaced variolation. Thanks to that discovery and developments in the ensuing years, smallpox began to fade. In 1980, nearly 200 years later, the World Health Organization (WHO) declared it eradicated.

Jenner's breakthrough paved the way for vaccines that today prevent widespread epidemics of a variety of diseases, including influenza, measles, polio, rabies, tetanus, typhoid, yellow fever, and cervical cancer.

How vaccines work

Your body's immune system is designed to seek and destroy invading pathogens—but it's not always easy, and pathogens can be clever. For example, the flu virus disguises itself as it enters your body and then begins to replicate before your immune system realizes that it's there. Vaccines give your immune system a leg up in the fight by teaching it how to quickly recognize a pathogen. There are several different types of vac-

cines, but they all essentially serve to introduce a germ or part of a germ into your body in a way that can't make you sick—though it may cause minor symptoms such as fever as your body builds immunity. Some vaccines use the entire pathogen, but in a killed or weakened state; some use only the parts of the organism that alert the immune system; some use a toxin made by the germ, and some rely on the pathogen's genetic material.

When you receive a vaccine, the germ sends up an alert to your immune system to start producing antibodies to fight it. Once your immune system has beaten the pathogen, it knows how to quickly destroy it. When you're exposed to the real thing, your body recognizes the bug and can fight off the infection before it begins.



Sometimes that immunity from a vaccine can last for years or even the rest of your life, while other vaccines require boosters at regular intervals. All adults and children need the influenza vaccine every year to prevent infection against the viral strains likely to be common that season.

Misinformation and waning trust in science and government has spurred an anti-vaccine movement among those who question their safety. Yet vaccines remain as crucial as ever to keeping dangerous diseases such as measles and polio at bay. The WHO estimates that vaccines save two million to three million lives each year.

Many are now pinning their hopes on a vaccine to do the same for the novel coronavirus. But it's too soon to say when that might be—or what type of vaccine will be most effective against the coronavirus that continues to spread around the world. (Courtesy [webmd.com](https://www.webmd.com) and <https://www.nationalgeographic.com>)

中华武术展暨第九届宏武杰出青年奖学金颁奖典礼



得獎學員頒獎後與主辦人吳而立、羅茜莉（中立者）合影。



榮獲宏武傑出青年獎學金的學生頒獎後與吳而立（右三）羅茜莉（中）合影。



本報記者秦鴻鈞攝影

全體參加學員與師父合影。



CKFA 武術學校表演。



羅茜莉指導的「精武體育會」學生表演。



出席頒獎儀式的師父（右起）釋延峰、釋行浩、奧斯汀廖施仁、楊俊義等人。



莊氏太極及功夫學校學生表演武術。



由楊俊義師父所指導的學生楊氏太極拳表演。



加州孟全勝師父指導的「全勝國際功夫學院」學生表演。



由釋延禪師父指導的少林寺文化中心學員表演少林功夫。



由 Travis AI 師父指導的少林武術學校表演。



Hu's Martial Arts School 學員武術表演。

休斯顿J区市议员Edward Pollard 带领社区居民进行春季环境建设整合活动精彩瞬间

